Propanc Biopharma Inc (PPCB)

$2.87 -5.13 (-64.13%)
Market Cap 155,000.00
Revenue (ttm) 0.00
Net Income (ttm) -1.82M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.03
Volume 489,547
Avg Vol 2,732
Day's Range N/A - N/A
Shares Out 19,000.00
Stochastic %K 94%
Beta 2.78
Analysts Strong Buy
Price Target $12.50

Company Profile

Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company has a research and collaboration agreement with the University of Jaén, to undertakes the r...

Industry: Biotechnology
Sector: Healthcare
Phone: 61 3 9882 0780
Fax: 61 3 9882 9969
Address:
302, 6 Butler Street, Camberwell, Australia
JohnTrack
JohnTrack Jan. 13 at 5:59 PM
$PPCB maybe later, for now watching
0 · Reply
MaddisonPrice0973
MaddisonPrice0973 Jan. 13 at 4:41 PM
$PPCB Research like this is why oncology timelines are long but meaningful. Blocking tumor support from cancer-associated fibroblasts isn’t about quick wins, it’s about weakening the system that helps tumors survive and spread. This kind of work won’t move charts overnight, but it’s the type of foundation real therapies are built on. https://d1io3yog0oux5.cloudfront.net/_136eb0d80789ccf188130a9b6c4079ef/propanc/db/261/693/pdf/Poster.pdf
0 · Reply
JohnTrack
JohnTrack Jan. 13 at 2:09 PM
$PPCB Provides Shareholder Update https://www.rapidticker.com/news/ppcb-propanc-biopharma-provides-shareholder-update-f03520
0 · Reply
JohnTrack
JohnTrack Jan. 12 at 12:17 PM
$PPCB keeping attention here...
0 · Reply
JohnTrack
JohnTrack Jan. 12 at 11:03 AM
$PPCB fresh headline just hit!!! https://www.rapidticker.com/news/ppcb-sec-filing-41532e
1 · Reply
IR_propancbiopharma
IR_propancbiopharma Jan. 10 at 4:58 PM
$PPCB Propanc enters 2026 with operational continuity and a defined scientific roadmap. Key activities include completing bioanalytical method validation, GMP manufacturing process development, and regulatory documentation to support the initiation of the planned Phase 1b First-in-Human study. Research collaborations continue strengthening the biological foundation of PRP, including work in resistant tumor models and follow-on recombinant proenzyme development for a fully synthetic version of the bovine derived ingredients. The Company will continue providing updates on validated scientific milestones as we advance PRP toward clinical evaluation in the new year.
1 · Reply
SuperGreenToday
SuperGreenToday Jan. 9 at 9:40 PM
$PPCB
1 · Reply
SoreNash19380
SoreNash19380 Jan. 9 at 3:48 PM
$PPCB Worth noting, though still a long road ahead. In biotech, incremental research like this is often necessary before anything meaningful happens. https://quantisnow.com/insight/propanc-biopharma-publishes-impact-of-proenzymes-on-pancreatic-ductal-adenocarcinoma-fibroblasts-in-peer-reviewed-6324644?utm_source=reddit
1 · Reply
IR_propancbiopharma
IR_propancbiopharma Jan. 8 at 9:35 PM
$PPCB Propanc has completed the administrative SEC filing tied to previously authorized financing arrangements. This filing is part of the standard procedural cycle for Nasdaq-listed biotechnology companies and ensures that all documentation remains current and aligned with reporting requirements. With this step finalized, the Company continues executing its operational plan for the coming quarters. Key activities include bioanalytical method validation, GMP manufacturing process development, and regulatory documentation to support the planned Phase 1b First-in-Human study. This administrative update does not alter Propanc’s scientific direction or development priorities. The strategic focus remains centered on advancing PRP through its defined preclinical milestones and maintaining a clear path toward clinical evaluation. Propanc will continue to communicate progress on validated scientific and regulatory outcomes as we move into the next stage of development.
0 · Reply
Eruption
Eruption Jan. 8 at 5:42 PM
$PPCB Finally had enough. Sold all shares at a HUGE loss. Absolutely criminal what this company has done. I didnt do my due diligence. I will pay for this very dearly, like many before me. Good luck to the rest of you.
0 · Reply
Latest News on PPCB
Propanc Biopharma Provides Shareholder Update

Jan 13, 2026, 8:45 AM EST - 1 day ago

Propanc Biopharma Provides Shareholder Update

Propanc Biopharma Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal

Dec 22, 2025, 7:00 AM EST - 23 days ago

Propanc Biopharma Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal

Propanc Biopharma Investigates “Mesenchymal Drift” to Reverse Chronic Diseases Defined by Altos Labs

Dec 4, 2025, 8:45 AM EST - 5 weeks ago

Propanc Biopharma Investigates “Mesenchymal Drift” to Reverse Chronic Diseases Defined by Altos Labs

Propanc Biopharma Requests Foreign Filing License from Spain for Methods of Treating Resistant Cancer and Fibrosis

Dec 1, 2025, 8:45 AM EST - 6 weeks ago

Propanc Biopharma Requests Foreign Filing License from Spain for Methods of Treating Resistant Cancer and Fibrosis

Propanc Biopharma Provides Corporate Update and Reports First Quarter 2025/26 Results

Nov 17, 2025, 8:45 AM EST - 2 months ago

Propanc Biopharma Provides Corporate Update and Reports First Quarter 2025/26 Results

Propanc Biopharma, Inc. Secures up to $100 Million Private Placement to Support Digital Asset Acquisition Strategy & Accelerate Company's R&D Pipeline

Nov 10, 2025, 8:45 AM EST - 2 months ago

Propanc Biopharma, Inc. Secures up to $100 Million Private Placement to Support Digital Asset Acquisition Strategy & Accelerate Company's R&D Pipeline

Propanc Biopharma, Inc. Pursues Strategic Acquisition Plan Targeting Digital Asset Treasury (DAT) Companies Trading Below Market Cap to Net Asset Value (MNAV)

Nov 4, 2025, 7:00 AM EST - 2 months ago

Propanc Biopharma, Inc. Pursues Strategic Acquisition Plan Targeting Digital Asset Treasury (DAT) Companies Trading Below Market Cap to Net Asset Value (MNAV)

CORRECTION: Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital

Oct 15, 2025, 5:45 PM EDT - 3 months ago

CORRECTION: Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital

Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital

Oct 15, 2025, 8:45 AM EDT - 3 months ago

Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital

Propanc Reports End of Fiscal Year Highlights and Outlines Therapeutic Development & $100M+ Digital Asset Treasury Strategy

Oct 7, 2025, 8:45 AM EDT - 3 months ago

Propanc Reports End of Fiscal Year Highlights and Outlines Therapeutic Development & $100M+ Digital Asset Treasury Strategy

Propanc Biopharma Receives Certificate of Grant for “Proenzyme Composition” Patent from US Patent & Trademark Office

Sep 17, 2025, 8:45 AM EDT - 4 months ago

Propanc Biopharma Receives Certificate of Grant for “Proenzyme Composition” Patent from US Patent & Trademark Office

Propanc Biopharma Announces Plan to Acquire $100 Million of Ethereum

Sep 2, 2025, 9:00 AM EDT - 4 months ago

Propanc Biopharma Announces Plan to Acquire $100 Million of Ethereum

Propanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQ

Aug 19, 2025, 8:30 AM EDT - 5 months ago

Propanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQ

U.S. IPO Weekly Recap: Bullish And Miami International Complete The Last Major IPOs Of The Summer

Aug 16, 2025, 12:25 AM EDT - 5 months ago

U.S. IPO Weekly Recap: Bullish And Miami International Complete The Last Major IPOs Of The Summer

BLSH BUUU KLAR MAGH MIAX NSRX NUTR

Propanc Biopharma Announces Nasdaq Uplisting and Pricing of $4 Million Public Offering

Aug 14, 2025, 11:00 PM EDT - 5 months ago

Propanc Biopharma Announces Nasdaq Uplisting and Pricing of $4 Million Public Offering

JohnTrack
JohnTrack Jan. 13 at 5:59 PM
$PPCB maybe later, for now watching
0 · Reply
MaddisonPrice0973
MaddisonPrice0973 Jan. 13 at 4:41 PM
$PPCB Research like this is why oncology timelines are long but meaningful. Blocking tumor support from cancer-associated fibroblasts isn’t about quick wins, it’s about weakening the system that helps tumors survive and spread. This kind of work won’t move charts overnight, but it’s the type of foundation real therapies are built on. https://d1io3yog0oux5.cloudfront.net/_136eb0d80789ccf188130a9b6c4079ef/propanc/db/261/693/pdf/Poster.pdf
0 · Reply
JohnTrack
JohnTrack Jan. 13 at 2:09 PM
$PPCB Provides Shareholder Update https://www.rapidticker.com/news/ppcb-propanc-biopharma-provides-shareholder-update-f03520
0 · Reply
JohnTrack
JohnTrack Jan. 12 at 12:17 PM
$PPCB keeping attention here...
0 · Reply
JohnTrack
JohnTrack Jan. 12 at 11:03 AM
$PPCB fresh headline just hit!!! https://www.rapidticker.com/news/ppcb-sec-filing-41532e
1 · Reply
IR_propancbiopharma
IR_propancbiopharma Jan. 10 at 4:58 PM
$PPCB Propanc enters 2026 with operational continuity and a defined scientific roadmap. Key activities include completing bioanalytical method validation, GMP manufacturing process development, and regulatory documentation to support the initiation of the planned Phase 1b First-in-Human study. Research collaborations continue strengthening the biological foundation of PRP, including work in resistant tumor models and follow-on recombinant proenzyme development for a fully synthetic version of the bovine derived ingredients. The Company will continue providing updates on validated scientific milestones as we advance PRP toward clinical evaluation in the new year.
1 · Reply
SuperGreenToday
SuperGreenToday Jan. 9 at 9:40 PM
$PPCB
1 · Reply
SoreNash19380
SoreNash19380 Jan. 9 at 3:48 PM
$PPCB Worth noting, though still a long road ahead. In biotech, incremental research like this is often necessary before anything meaningful happens. https://quantisnow.com/insight/propanc-biopharma-publishes-impact-of-proenzymes-on-pancreatic-ductal-adenocarcinoma-fibroblasts-in-peer-reviewed-6324644?utm_source=reddit
1 · Reply
IR_propancbiopharma
IR_propancbiopharma Jan. 8 at 9:35 PM
$PPCB Propanc has completed the administrative SEC filing tied to previously authorized financing arrangements. This filing is part of the standard procedural cycle for Nasdaq-listed biotechnology companies and ensures that all documentation remains current and aligned with reporting requirements. With this step finalized, the Company continues executing its operational plan for the coming quarters. Key activities include bioanalytical method validation, GMP manufacturing process development, and regulatory documentation to support the planned Phase 1b First-in-Human study. This administrative update does not alter Propanc’s scientific direction or development priorities. The strategic focus remains centered on advancing PRP through its defined preclinical milestones and maintaining a clear path toward clinical evaluation. Propanc will continue to communicate progress on validated scientific and regulatory outcomes as we move into the next stage of development.
0 · Reply
Eruption
Eruption Jan. 8 at 5:42 PM
$PPCB Finally had enough. Sold all shares at a HUGE loss. Absolutely criminal what this company has done. I didnt do my due diligence. I will pay for this very dearly, like many before me. Good luck to the rest of you.
0 · Reply
Eruption
Eruption Jan. 8 at 1:07 PM
More "great" news...what a disaster...​ $PPCB https://www.tipranks.com/news/company-announcements/propanc-biopharma-receives-nasdaq-minimum-bid-price-notice
0 · Reply
JohnTrack
JohnTrack Jan. 8 at 3:13 AM
$PPCB watching if it holds up!
0 · Reply
Jags1000
Jags1000 Jan. 7 at 11:17 PM
$PPCB @IR_propancbiopharma please don’t do another RS
0 · Reply
JohnTrack
JohnTrack Jan. 7 at 10:56 PM
$PPCB no compliance notice https://www.rapidticker.com/news/ppcb-sec-filing-a09d20
0 · Reply
Jags1000
Jags1000 Jan. 7 at 10:25 PM
$PPCB 8-K delisting notice by NASDAQ
0 · Reply
Steve7774
Steve7774 Jan. 7 at 4:11 PM
$PPCB The stock is falling every day
0 · Reply
WaveRider666
WaveRider666 Jan. 7 at 3:04 PM
$PPCB - LOL Funny to see PPCB Investors Relations posting desperately in this group. Meanwhile, $PPCB share price....
1 · Reply
LiSor792
LiSor792 Jan. 7 at 2:19 PM
$PPCB I personally think this is still very early but having a research published matters. Yes, It doesn’t reduce the risk but it really gives this trial more credibility which is really what both patients and shareholders want to see over time. https://www.propanc.com/news-media/press-releases/detail/181/propanc-biopharma-publishes-impact-of-proenzymes-on
0 · Reply
IR_propancbiopharma
IR_propancbiopharma Jan. 6 at 2:12 AM
$PPCB Propanc closes the year with a defined scientific agenda and steady operational progress. Our work remains centered on advancing PRP through the clinical preparatory, bioanalytical, and regulatory activities required for the planned Phase 1b First-in-Human study. Throughout the year, the Company has focused on strengthening the scientific foundation of the program, expanding research insights, and advancing the steps that support future clinical execution. This direction remains unchanged as we enter the new year. We appreciate the continued support from our community as we advance a development program grounded in evidence, precision, and long-term therapeutic potential.
1 · Reply
MacAwoo
MacAwoo Jan. 2 at 3:34 PM
$PPCB got ugly fast 😳😱
0 · Reply
IR_propancbiopharma
IR_propancbiopharma Dec. 31 at 3:15 PM
$PPCB Market and trading dynamics can impact share price movements in the short term. Our priority continues to be delivering progress against our long-term objectives.
0 · Reply
IR_propancbiopharma
IR_propancbiopharma Dec. 29 at 5:08 PM
$PPCB Propanc Biopharma Publishes Peer-Reviewed Study on PRP and PDAC Fibroblasts Propanc Biopharma announced that its joint research with the Universities of Jaén and Granada has resulted in a peer-reviewed publication in Scientific Reports detailing the impact of proenzymes on pancreatic ductal adenocarcinoma (PDAC) fibroblasts. The study describes multifaceted effects of PRP on cancer-associated fibroblasts and tumor cells, highlighting its role within the tumor microenvironment. The findings underscore Propanc’s scientific progress in understanding biological interactions that may inform future translational work. Future clinical investigation is planned, with PDAC among the target indications in one of two Phase 2 proof-of-concept studies following completion of the Phase 1b study. This reflects rigorous collaboration with academic partners and reinforces the Company’s commitment to advancing data-driven oncology research. Read more here: https://ir.propanc.com/press-releases/detail/181/propanc-biopharma-publishes-impact-of-proenzymes-on
0 · Reply